Pulmonary Embolism Pipeline Insight 2025: Novel Anticoagulants, Thrombolytics, and Device-Based Therapies Redefining Acute and Chronic Management | DelveInsight

DelveInsight's "Pulmonary Embolism - Pipeline Insight, 2025" explores the advancing treatment landscape for pulmonary embolism, a life-threatening condition resulting from obstruction of the pulmonary arteries, most often due to venous thromboembolism. Current management primarily relies on anticoagulation with heparins, vitamin K antagonists, or direct oral anticoagulants, and in severe cases, systemic thrombolysis or catheter-directed interventions. While these approaches improve survival, they are limited by bleeding risks, suboptimal clot resolution, and a lack of durable prevention of recurrence.

The pipeline is evolving toward safer and more effective strategies that address both acute management and long-term prevention. Next-generation anticoagulants are being designed with improved selectivity and reduced bleeding liability, aiming to provide a more favorable risk-benefit profile compared to existing oral agents. Meanwhile, novel thrombolytics with fibrin specificity and targeted delivery methods are being evaluated to enhance clot dissolution while minimizing systemic exposure.

Beyond pharmacology, device-based approaches such as mechanical thrombectomy and catheter-directed therapies are advancing, with several new platforms under investigation to restore pulmonary blood flow in high rapidly- and intermediate-risk patients. These technologies are increasingly studied alongside pharmacological therapies, positioning combination approaches as a potential standard in complex PE management.

Clinical trials are also incorporating broader outcome measures, including right ventricular function recovery, recurrence rates, chronic thromboembolic pulmonary hypertension (CTEPH) prevention, and quality-of-life assessments. This shift reflects a growing focus not only on acute survival but also on long-term cardiopulmonary health.

With multiple late-stage candidates and devices advancing under regulatory guidance, the pulmonary embolism treatment paradigm is poised to shift from generalized anticoagulation toward precision-based, multimodal interventions. The future of PE management lies in integrating safer anticoagulants, next-generation thrombolytics, and innovative devices to deliver durable protection, reduce complications, and improve overall patient outcomes.

Interested in learning more about the current treatment landscape and the key drivers shaping the pulmonary embolism pipeline? Click here: https://www.delveinsight.com/report-store/pulmonary-embolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Pulmonary Embolism Pipeline Report
• DelveInsight's pulmonary embolism pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for Pulmonary Embolism treatment.
• The leading pulmonary embolism companies include Translational Sciences, Supergene, Angde Biotech Pharmaceutical, Yuhan, and others are evaluating their lead assets to improve the Pulmonary Embolism treatment landscape.
• Key pulmonary embolism pipeline therapies in various stages of development include TS 23, Recombinant staphylokinase (Supergene), Reteplase, YHP 1906, and others.
• In September 2025, Imperative Care received FDA 510(k) clearance for its Symphony® Thrombectomy System to treat pulmonary embolism (PE), expanding its previous use in venous thrombosis to address the full spectrum of venous thromboembolism (VTE).
• In September 2025, 4D Medical received FDA 510(k) clearance for its CT VQ scan, the first non-contrast imaging tool providing quantitative ventilation and perfusion analysis from standard chest CTs. This technology aids in detecting pulmonary embolism, assessing CTEPH and other lung conditions, and supporting surgical planning.
• In September 2024, Jupiter Endovascular, Inc. treated its first two patients in the SPIRARE I study (NCT06571760), evaluating the Vertex Pulmonary Embolectomy System with Endoportal ControlTM technology for Acute Pulmonary Embolism. The initial cases took place at St. John Paul II Hospital in Krakow, Poland, affiliated with Jagiellonian University.

Request a sample and discover the recent breakthroughs happening in the pulmonary embolism pipeline landscape at https://www.delveinsight.com/report-store/pulmonary-embolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pulmonary Embolism Overview
Pulmonary embolism (PE) is a serious condition caused by a blockage in one of the pulmonary arteries, usually due to a blood clot that travels from the legs or other parts of the body (deep vein thrombosis). This blockage restricts blood flow to the lungs, which can lead to lung damage, decreased oxygen levels, and can be life-threatening if untreated. Symptoms often include sudden shortness of breath, chest pain, rapid heart rate, and coughing, sometimes with blood.

Early diagnosis and treatment are critical and typically involve anticoagulants to prevent further clotting, thrombolytics to dissolve clots, or surgical interventions in severe cases. Risk factors include prolonged immobility, surgery, certain medical conditions, and genetic predisposition. Pulmonary embolism is a major cause of cardiovascular death worldwide, highlighting the importance of awareness and timely management.

Find out more about pulmonary embolism medication at https://www.delveinsight.com/report-store/pulmonary-embolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pulmonary Embolism Treatment Analysis: Drug Profile
Recombinant Staphylokinase: Supergene
Recombinant staphylokinase, with Forteplase as its active ingredient, is a single-chain molecule composed of 138 amino acids. In human plasma containing a fibrin clot, it selectively binds to plasmin at the clot surface, forming a plasmin-staphylokinase complex that aids clot breakdown. The drug is currently in Phase III clinical trials for the treatment of pulmonary embolism.

Learn more about the novel and emerging pulmonary embolism pipeline therapies at https://www.delveinsight.com/report-store/pulmonary-embolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pulmonary Embolism Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Pulmonary Embolism Pipeline Report
• Coverage: Global
• Key Pulmonary Embolism Companies: Translational Sciences, Supergene, Angde Biotech Pharmaceutical, Yuhan, and others.
• Key Pulmonary Embolism Pipeline Therapies: TS 23, Recombinant staphylokinase (Supergene), Reteplase, YHP 1906, and others.

To dive deep into rich insights for drugs used for pulmonary embolism treatment, visit: https://www.delveinsight.com/report-store/pulmonary-embolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Pulmonary Embolism Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Pulmonary Embolism Pipeline Therapeutics
6. Pulmonary Embolism Pipeline: Late-Stage Products (Phase III)
7. Pulmonary Embolism Pipeline: Mid-Stage Products (Phase II)
8. Pulmonary Embolism Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.